Preclinical research on medical cannabis and cannabis-derived compounds has demonstrated significant potential in the treatment of various immune-related disorders, including some types of pain, inflammatory bowel disease (IBD), rheumatic disease, atherosclerosis, and atopic dermatitis, primarily through CB2 activation [95,197,321]. This evidence concerns the gene CNR2 and inflammatory bowel disease.